KIDS · OrthoPediatrics

The thesis

OrthoPediatrics shares are more likely to lag the S&P 500 over the next three months because the price already sits above most analyst valuations after a strong quarter. The shares closed at $33.67 on 11 November 2026, above six of the seven price targets that brokers raised on 28 October 2026. Preliminary fourth-quarter revenue, expected around mid-January 2027, is the first hard test of whether sales justify that price.

The business is improving. Third-quarter revenue rose 19% to a record $72.7 million, and on 27 October 2026 the company raised its 2026 revenue guidance to $270.0–$273.0 million. At the Stifel 2026 Healthcare Conference on 11 November 2026, Chief Executive Dave Bailey said the company targets at least $6 million of fourth-quarter free cash flow and called the competitive field "increasingly benign," according to Investing.com's account of the session.

The same session set limits on the fourth quarter. Management called it seasonally weaker than the third, cited a tough comparison against large prior-year 7D orders, and said it is limiting Latin American set sales to improve collections. Bailey said guidance would stay "relatively conservative" and gave no 2027 outlook. Stifel's moderator, Rick Wise, put fourth-quarter revenue near $69 million; management did not confirm the figure.

The rating is Low because the 34.6% three-month gain to the 11 November 2026 close prices in continued high-teens growth that management's own fourth-quarter commentary does not promise.

Bullish and bearish views on OrthoPediatrics Corp.

The bull case on OrthoPediatrics Corp. (KIDS), in brief: third-quarter growth was broad. The bear case: the price sits above most targets.

Bull case

• Third-quarter growth was broad. According to the company's 27 October 2026 release, revenue rose 19% to $72.7 million from $61.2 million, with US sales up 19% and international up 18%. Trauma & Deformity grew 19% to $52.6 million and Scoliosis 18% to $19.2 million; Bailey said on 11 November 2026 the quarter relied on no one-time sales.
• Full-year guidance moved up. On 27 October 2026 the company raised 2026 revenue guidance to $270.0–$273.0 million from $265.0–$269.0 million. It kept its target of about $25 million in adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation, excluding one-off items).
• Cash flow is turning positive. Third-quarter free cash flow was $1.6 million, against $3.4 million used a year earlier, and adjusted EBITDA was a record $6.9 million against $6.2 million, per the 27 October 2026 release. On 11 November 2026 management targeted at least $6 million of fourth-quarter free cash flow and breakeven for 2026.
• VerteGlide is already in 40-plus hospitals. The company moved its VerteGlide Spinal Growth Guidance System for early onset scoliosis to full commercial release on 9 November 2026. At Stifel on 11 November 2026, Bailey said more than 40 hospitals were using it, with repeat use, and that it "is going to be big for us next year."
• The next scoliosis product is close. Bailey said on 11 November 2026 that an FDA investigational device exemption (IDE) for eLLi was expected "at any moment," with first cases in early 2027. He said eLLi probably has a larger market than VerteGlide.
• Brokers raised targets together. On 28 October 2026, according to Benzinga, Lake Street raised its target to $38; Canaccord Genuity, Piper Sandler and BTIG to $30; TD Cowen and Truist to $28; and Stifel to $27.

Bear case

• The price sits above most targets. The 11 November 2026 close of $33.67 is above six of the seven targets raised on 28 October 2026. Only Lake Street's $38 is higher, and Truist rates the shares Hold.
• The fourth quarter faces hard comparisons. On the 27 October 2026 call, management said the quarter may not repeat prior-year one-off set sales to Brazil and large 7D orders. On 11 November 2026 it added that it is limiting Latin American set sales and cutting payment terms for stocking distributors.
• The largest holder sold during the climb. SEC Form 4 filings show Squadron Capital LLC, a 10% owner, sold 336,831 shares at an average $23.04 from 28 August to 1 September 2026, 22,500 at $23.35 on 2 September 2026 and 302,369 at $21.01 on 10 September 2026. Jennifer Pritzker and director David Pelizzon filed matching reports for the same sales.
• The company still loses money. The third-quarter net loss was $5.9 million, or $0.25 per share. Adjusted earnings per share of $(0.23) missed the $(0.21) estimate, according to Benzinga.
• Debt exceeds cash. On 30 September 2026, cash, short-term investments and restricted cash totalled $44.9 million, down from $62.9 million at 31 December 2025, against a $48.6 million term loan and a $49.0 million convertible note.
• Inventory will absorb cash in 2027 and 2028. Bailey said on 11 November 2026 that the company will reinvest part of its EBITDA growth into inventory over those two years and does not aim to maximise free cash flow.

Price setup

The shares closed at $33.67 on 11 November 2026, 2.5% below the 52-week intraday high of $34.53 set on 4 November 2026. Since that day, closes have ranged from $31.76 on 6 November 2026 to $33.99 on 9 November 2026, so the price has stalled near its high after the post-earnings run.

The 3-month gain is 34.6%, measured from a $25.01 close on 13 August 2026. As of 11 November 2026, the 50-day moving average is $24.68 and the 200-day moving average is $20.13, both well below the price. The 52-week closing low is $14.64, set on 29 April 2026.

The analyst targets show where brokers valued the business after the report. Canaccord Genuity, Piper Sandler and BTIG are at $30 and Stifel is at $27, all below the 11 November 2026 close. Lake Street's $38 is the only published target above it.

Catalysts ahead

• 2 December 2026: Piper Sandler 38th Annual Healthcare Conference fireside chat, 4:00 pm ET. This is the last scheduled management appearance before year-end; it shows whether the fourth-quarter framing, VerteGlide hospital count or eLLi timing has moved since 11 November 2026.
• ~15 January 2027 (est.): Preliminary fourth-quarter and full-year 2026 revenue. This is the first hard read on whether full-year sales land inside, below or above the $270.0–$273.0 million guidance against the Brazil and 7D comparisons.
• ~3 March 2027 (est.): Fourth-quarter 2026 report and 2027 guidance. It shows whether fourth-quarter free cash flow reached the $6 million target and whether 2027 guidance supports a price above most analyst targets.

What would change the view

A daily close above $36.70, beyond the 4 November 2026 intraday 52-week high of $34.53, would show the shares leading the S&P 500. Preliminary fourth-quarter revenue that lifts full-year 2026 sales above the $273.0 million top of guidance would also prove the call wrong.

What it trades with

OrthoPediatrics trades with a small group of medtech and diagnostics names, including Enovis, Vericel, AxoGen and Glaukos. Its sales depend on pediatric procedure volumes, school-calendar seasonality and children's hospital contracting, so its own results drive the shares more than any shared theme. A broad sell-off in small-cap medtech would still likely pull the shares down with peers, whatever fourth-quarter sales turn out to be. Further sales by Squadron Capital, which reported three blocks between 28 August 2026 and 10 September 2026, would add supply that has nothing to do with the sector.